Summary of Product Characteristics
last updated on the eMC:
07/05/2009
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 07/05/2009 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.2 - Posology and method of administration
-
Change to section 7 - Marketing Authorisation Holder
-
Change to section 9 - Date of first Authorisation/renewal of the Authorisation
-
Change to section 10 date of revision of the text
|
| Date of revision of text on the SPC: 02-Dec-2008 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
4..2 Posology and method of administration
recommended children’s dosage regimen has been updated
Children: The suggested dose is 1.4 to 2 mg/m2 given on a weekly basis with a maximum weekly dose of 2 mg. For children weighing 10 kg or less the starting dose should be 0.05 mg/kg administered as a weekly intravenous injection.
MARKETING AUTHORISATION HOLDER
Address change:
Hospira UK Limited
Queensway
Royal Leamington Spa
Warwickshire
CV31 3RW
Date changes to the below:
9. DATE OF RENEWAL OF AUTHORISATION
October 1995/ 2nd December 2008
10. DATE OF (PARTIAL) REVISION OF THE TEXT
2nd December 2008
|
|
Updated on 07/07/2004 and displayed until 07/05/2009
|
Reasons for adding or updating:
|
-
Change to section 4.3 - Contra-indications
-
Change to section 4.4 - Special Warnings and Precautions for Use
-
Change to section 6.2 - Incompatibilities
|
|
Updated on 26/09/2003 and displayed until 07/07/2004
|
Reasons for adding or updating:
|
-
Change to section 7 - Marketing Authorisation Holder
|
|
Updated on 22/08/2001 and displayed until 26/09/2003
|
Reasons for adding or updating:
|
-
Change to section 1 - trade name
|
|